Editas Medicine, Inc. (EDIT)
3.23
+0.15
(+4.87%)
USD |
NASDAQ |
Sep 04, 16:00
3.19
-0.04
(-1.24%)
After-Hours: 20:00
Editas Medicine SG&A Expense (TTM) : 45.51M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 45.51M |
| March 31, 2026 | 46.76M |
| December 31, 2025 | 49.90M |
| September 30, 2025 | 54.90M |
| June 30, 2025 | 60.68M |
| March 31, 2025 | 66.02M |
| December 31, 2024 | 71.99M |
| September 30, 2024 | 70.09M |
| June 30, 2024 | 66.99M |
| March 31, 2024 | 65.98M |
| December 31, 2023 | 69.65M |
| September 30, 2023 | 73.18M |
| June 30, 2023 | 74.43M |
| March 31, 2023 | 74.16M |
| December 31, 2022 | 70.70M |
| September 30, 2022 | 69.24M |
| June 30, 2022 | 69.19M |
| March 31, 2022 | 74.28M |
| December 31, 2021 | 76.18M |
| September 30, 2021 | 75.44M |
| June 30, 2021 | 79.20M |
| March 31, 2021 | 71.25M |
| December 31, 2020 | 67.57M |
| Date | Value |
|---|---|
| September 30, 2020 | 68.70M |
| June 30, 2020 | 64.50M |
| March 31, 2020 | 64.83M |
| December 31, 2019 | 64.55M |
| September 30, 2019 | 60.81M |
| June 30, 2019 | 58.41M |
| March 31, 2019 | 58.31M |
| December 31, 2018 | 55.01M |
| September 30, 2018 | 55.52M |
| June 30, 2018 | 54.82M |
| March 31, 2018 | 52.40M |
| December 31, 2017 | 50.50M |
| September 30, 2017 | 49.86M |
| June 30, 2017 | 48.52M |
| March 31, 2017 | 48.79M |
| December 31, 2016 | 46.26M |
| September 30, 2016 | 40.55M |
| June 30, 2016 | 33.46M |
| March 31, 2016 | 24.58M |
| December 31, 2015 | 18.10M |
| September 30, 2015 | 10.76M |
| June 30, 2015 | 6.554M |
| March 31, 2015 | 3.273M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Recursion Pharmaceuticals, Inc. | 151.41M |
| Geron Corp. | 154.96M |
| Halozyme Therapeutics, Inc. | 238.00M |
| Novavax, Inc. | 121.22M |
| AVITA Medical, Inc. | 81.89M |